
    
      A two-phase, single center, observational study of 25 subjects to assess 4 weeks of
      adjunctive therapy of Enstilar® QD followed by 12 weeks QD on two consecutive days a week to
      patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks
    
  